Recent Company News

• 04:44 AM ET Dec 22, 2025
  

  Eisai CFO Mitsuru Shomon to retire, effective 31-Dec (¥4512.0000, 0)

• 02:14 PM ET Dec 12, 2025
  

  Tiziana Life Sciences to dose first patient in Phase 2 Alzheimer's Trial ($1.68, -0.04)

• 06:42 PM ET Dec 08, 2025
  

  Eisai, Biogen's anti-Aβ protofibril antibody LEQEMBI included in National Reimbursement Drug List (¥4673.0000, 0)

• 01:04 AM ET Dec 08, 2025
  

  Newron Pharmaceuticals initiates its ENIGMA-TRS 2 Phase III study in the US with evenamide as an add-on therapy for patients with TRS (CHF 18.28, 0.00)

• 07:15 PM ET Dec 07, 2025
  

  Hutchmed provides 2025 NRDL update; continue to include ELUNATE, ORPATHYS and SULANDA (HK$22.00, 0.00)

• 04:35 PM ET Dec 07, 2025
  

  Eisai initiated neutral at SBI Securities Japan (¥4668.0000, 0)

• 06:17 PM ET Dec 03, 2025
  

  Eisai presents new data on continued and expanding benefit of LEQEMBI at CTAD conference (¥4683.0000, 0)

• 07:38 PM ET Dec 01, 2025
  

  Eisai presents new data from E2814-103 study of etalanetug at CTAD 2025 (¥4688.0000, -102)

• 08:42 AM ET Dec 01, 2025
  

  Germany's IQWiG says additional benefit of lecanemab compared to previous standard of care in Germany has not been proven

• 12:45 AM ET Nov 28, 2025
  

  Eisai applies in Japan for approval of Leqembi as drug with new administration route (09:32 JT/01:32 CET/19:32 ET) (¥4894.0000, -1)